Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 6/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642241 | 1.00 | LMNA (0.36) | LMNAHPGDPADI4NR1H2TLR9 | |
| SCHEMBL29642372 | 0.83 | PADI4 (0.50) | LMNAHPGDPADI4 | |
| SCHEMBL30411578 | 0.78 | LMNA (0.42) | LMNAHPGDPPARG | |
| SCHEMBL23971164 | 0.78 | LMNA (0.42) | LMNAHPGDPPARG | |
| SCHEMBL29642366 | 0.74 | PADI4 (0.53) | PADI4 | |
| SCHEMBL24568058 | 0.74 | PADI4 (0.53) | PADI4 | |
| SCHEMBL24568632 | 0.73 | NR1H2 (0.35) | NR1H2NR1H3 | |
| SCHEMBL23971162 | 0.72 | KDM5A (0.38) | LMNAHPGD | |
| SCHEMBL29642296 | 0.72 | KDM5A (0.38) | LMNAHPGD | |
| SCHEMBL23970708 | 0.70 | GRM5 (0.37) | NR1H2TLR9TLR7NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | LMNA 2684/4885HPGD 729/4885PADI4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.